EyePoint Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary Moby Intelligence Thu, November 12, 2026 at 1:17 PM EST 3 min read NVDA -4.51% EYPT -8.20% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
The discontinuation of the wet AMD program follows Phase III trials failing to meet primary endpoints, despite demonstrating biological activity and superior treatment burden reduction.
Management is pivoting resources toward Diabetic Macular Edema (DME) based on the disease's distinct inflammatory biology, where DURAVYU'S JAK1 inhibition addresses IL-6-driven vascular dysfunction.
A 53% workforce reduction was implemented to align the cost structure with a singular focus on the DME clinical program and preserve financial flexibility.
Confidence in the DME program is bolstered by Phase II VERONA data, which showed rapid efficacy and superior fluid control compared to aflibercept.
The strategic shift leverages DURAVYU'S multi-mechanism of action to target the high discontinuation rates in the $5 billion global DME market.
Top-line results for the pivotal COMO and CAPRI Phase III DME trials are expected early in the fourth quarter of 2027.
Current cash reserves of $118 million are projected to fund operations into late Q3 2027, necessitating additional capital or strategic actions to reach the DME data milestone.
Management is actively evaluating business development opportunities and operational adjustments to extend the financial runway beyond the current Q3 2027 estimate.
The regulatory strategy for a potential DME filing will incorporate the extensive safety database generated from the discontinued wet AMD trials.
The 53% workforce reduction is expected to generate approximately $30 million in annualized savings once fully implemented.
A protocol amendment for the DME trials tightened the rescue criteria to a five-letter vision loss to better protect the non-inferiority margin.
The company is exploring the identification of specific biomarkers or patient subgroups from wet AMD data that could potentially justify a future re-entry into that indication.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Management amended the supplement injection threshold from a 10-letter decline to a 5-letter decline to preserve visual acuity outcomes.
The change aims to ensure that visual improvements are attributed to the study drug rather than rescue medications.
Management acknowledged the current runway ends just before the expected data release and is evaluating multiple levers to bridge the gap.
The priority is to ensure the organization reaches and passes the DME data milestone without running out of capital.
DME patients are typically younger with fewer age-related comorbidities like fibrosis or geographic atrophy, potentially leading to more homogenous trial data.
Management believes the DME trials are adequately powered to handle the decreasing variability seen in modern diabetic patient populations.
EyePoint is leaving no stone unturned in seeking value-creating opportunities, including potential partnerships for the DME program.
Conversations include exploring whether specific biomarkers from the failed wet AMD trials could support a niche pathway for that indication.
